#Shanghai #USA #Pulnovo Medical #ESC Congress #PADN-HF-PH

Pulnovo Medical's Landmark PADN-HF-PH Trial Results

In a momentous announcement during the European Society of Cardiology (ESC) Congress 2026, Pulnovo Medical showcased pivotal findings from the PADN-HF-PH clinical trial, which were also published in the prestigious New England Journal of Medicine (NEJM) on the same day. This trial, highlighted at Hot Line 6, is a beacon in the field of cardiovascular interventions, setting a new standard for managing patients with pulmonary hypertension stemming from left heart disease (PH-LHD).

Background of the Study

The PADN-HF-PH trial, orchestrated by a collaboration of leading institutions and researchers including Professor Shao-Liang Chen and Academician Yaling Han, involved 264 patients and sought to assess the efficacy of the Pulmonary Artery Denervation (PADN) System when added to Guideline-Directed Medical Therapy (GDMT). Patients with PH-LHD endure complications where pulmonary hypertension and left-sided heart afflictions exacerbate one another, leading to increased symptoms and unfavorable clinical outcomes.

Key Findings of the Trial

The results from this well-structured, randomized clinical trial revealed groundbreaking statistics that have significant implications for future therapies. The analysis showed:

• - 51% Reduction in Clinical Worsening: Over a median follow-up period of 338 days, only 25.7% of those treated with PADN and GDMT experienced clinical worsening compared to 51.5% for those receiving GDMT alone. This translates into a hazard ratio of 0.49, indicating a substantial protective effect by the PADN therapy.
• - Decrease in Recurrent Clinical Events: The annualized incidence of recurrent events was found to be 36.3 per 100 patient-years in the PADN group, contrasting sharply with 56.3 per 100 patient-years in the GDMT group, marking a 35.5% decrease in the burden of the disease.
• - Enhanced Functional Capacity: Patients undergoing PADN displayed a measurable improvement in their functional status, achieving an average increase of 24.8 meters in their 6-minute walk distance over the year, suggesting better quality of life.
• - Quality of Life Improvements: Higher scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) indicated improved health status, aligning with decreases in biomarkers like NT-proBNP, essential indicators of heart function.
• - Favorable Safety Profile: The PADN procedure presented a favorable safety profile, with minimal complications reported among participants, underscoring its viability as a treatment option.

Implications for Future Therapies

The PADN-HF-PH trial's findings not only provide clinical evidence supporting the use of PADN in conjunction with GDMT but also highlight the need for targeted therapies addressing pulmonary hypertension specifically, which has been a critical gap in current treatment frameworks. The trial's comprehensive approach to evaluating clinical outcomes reflects the potential for a paradigm shift in how PH-LHD is treated, moving beyond merely managing heart failure to specifically addressing the underlying pulmonary conditions.

About Pulnovo Medical

Pulnovo Medical stands at the forefront of innovation in the realm of pulmonary hypertension and heart failure treatments. By leveraging their proprietary PADN technology, the company is not only adhering to evolving clinical standards but also progressing toward addressing unmet needs in a significant patient population. As they move forward in expanding clinical applications across various forms of pulmonary hypertension, their commitment to improving patient outcomes remains unwavering. For further details about their innovations and clinical developments, visit Pulnovo Medical's website.

The outcomes from this trial mark a turning point in interventional cardiology, paving the way for new guidelines and treatment strategies that may soon redefine patient care.